Most people switch for one of two reasons. The scale stopped moving on tirzepatide, or they've seen what retatrutide did in trials and want the next step. Switching from tirzepatide to retatrutide is simpler than most guides make it sound, but three details decide how the first month goes: the day you take the first shot, the dose you start on, and how you read the new vial.
🔑 Key Takeaways
- There's no official tirzepatide-to-retatrutide dose conversion, and knowing why tells you where to restart
- The standard switch day needs no washout, and the half-life math shows why
- Copying your old syringe units can more than double your first retatrutide dose
- One retatrutide side effect is about 30 times more common than it was on tirzepatide
- The first head-to-head trial of the two drugs finishes in December 2026
Below: the timing options, where to start for your situation, a 20-week schedule and what to watch for in the first month. The last section covers when staying on tirzepatide is the smarter call.
Why People Switch From Tirzepatide to Retatrutide
Usually, the scale has stopped moving. You've climbed the tirzepatide ladder, the weekly loss has shrunk to almost nothing, and the next dose increase doesn't seem to change much. That's when retatrutide starts to look interesting.
Tirzepatide works on two gut hormones, GIP and GLP-1. Retatrutide, the drug often sold online as GLP-3, adds a third: glucagon. The glucagon signal pushes the body to burn more energy and more liver fat, which is the leading explanation for why its trial numbers run higher.
*Both weight-loss figures count everyone who started treatment, including people who stopped. Among people who stayed on treatment, the averages were 22.5% for tirzepatide and 28.3% for retatrutide (see the full TRIUMPH-1 results). They come from separate trials of different lengths, so read the gap as a direction, not an exact difference. Our retatrutide vs tirzepatide comparison covers the rest of the data.
One thing nobody can tell you yet is whether retatrutide restarts weight loss in people who stalled on tirzepatide. No trial has tested a switch. TRIUMPH-5 (NCT06662383), which randomized about 800 adults to one drug or the other, is the first head-to-head comparison, and it is scheduled to finish in December 2026.
Is There a Tirzepatide to Retatrutide Dose Conversion?
No, and the reason matters. The two drugs don't activate their receptors with the same strength per milligram, so 10 mg of one isn't worth a fixed amount of the other.
The trial numbers make this obvious. In TRIUMPH-1, 4 mg of retatrutide produced 17.6% average weight loss. In SURMOUNT-1, tirzepatide needed between 5 mg (15.0%) and 10 mg (19.5%) to land in the same range. Similar results, very different milligrams.
Some sites publish conversion charts, such as “10 mg of tirzepatide equals 2 to 3 mg of retatrutide.” None of them cite a study, because no study has made that conversion. What the trials do give you is a starting dose, 2 mg, and a pace: four weeks on each dose before the next step. It's the same logic as the tirzepatide dosage chart you already followed, applied to a new drug.
When to Take Your First Retatrutide Dose
Most people take it on their next injection day. That's seven days after your last tirzepatide shot, the same weekly rhythm you're used to.
It sounds like it would stack the two drugs. It mostly doesn't. Tirzepatide has a half-life of about five days, so by day seven your level has already fallen to the low point it reaches before every dose. Starting retatrutide then adds a small first dose on top of tirzepatide you'd have had anyway, and that tirzepatide keeps fading over the next three weeks.
Figures are approximate, based on a five-day half-life, and real levels vary from person to person. If you've changed GLP-1 drugs before, for example from semaglutide to tirzepatide, the timing logic is the same.
A long washout doesn't make the switch safer for most people. It mainly trades a small overlap for a few weeks of returning appetite before retatrutide builds up. The exception is anyone still dealing with nausea, vomiting or constipation on tirzepatide, where a 10 to 14 day gap lets the gut settle before a new drug arrives.
One rule has no exceptions: never take tirzepatide and retatrutide in the same week. Both act on the GIP and GLP-1 receptors, and the combination has never been tested.
What Dose Should You Start Retatrutide On?
Start low, even if tirzepatide felt easy. Every phase 3 retatrutide trial started people on 2 mg a week, whatever dose they were heading for. In the phase 2 trial, gut side effects were partly reduced by starting at 2 mg instead of 4 mg.
Your tolerance to tirzepatide helps, because the GIP and GLP-1 parts are shared. The glucagon part is new, though, and your body has never had it before.
Expect the first month at 2 mg to feel a little weaker than your last month on tirzepatide, especially if you were on 12.5 or 15 mg. That dip is temporary. The next step, 4 mg, is already a full maintenance dose in the phase 3 trials.
A 20-Week Switching Schedule
Here's the phase 3 ladder, week by week. Each dose runs for four weeks, which is roughly how long retatrutide's six-day half-life takes to build to a steady level.
You don't have to climb all the way. TRIUMPH-1 kept people on 4, 9 or 12 mg, and among those who stayed on treatment the averages were 19.0%, 25.9% and 28.3% at 80 weeks. The top dose also had the most dropouts: 11.3% stopped because of side effects, against 4.9% on placebo. Many people settle on the lowest dose that keeps them losing. Our retatrutide dosing schedule covers each step in more detail.
Don't Reuse Your Tirzepatide Syringe Units
Your old unit count means nothing now. Units measure volume, not dose, and the dose in each unit depends on how the vial was mixed.
Say you drew 50 units from a 20 mg tirzepatide vial mixed with 2 mL of water. That vial holds 10 mg per mL, so 50 units was 5 mg. A 30 mg retatrutide vial mixed with 3 mL is also 10 mg per mL, so the same 50 units would be 5 mg of retatrutide, two and a half times the 2 mg starting dose. The right draw is 20 units.
Our retatrutide dosage calculator works out the units for any vial size and water amount, and the retatrutide reconstitution guide walks through mixing step by step.
All of this math assumes the vial holds exactly what its label says. If you're comparing retatrutide for sale, check that the certificate of analysis matches the batch number on your vial and shows both purity and actual mass. A 30 mg vial that really holds 24 mg makes every dose 20% weaker without you noticing.
What Changes After You Switch
Most of it will feel familiar. The common side effects are the gut effects you know from tirzepatide, and they behave the same way: they show up after a dose increase and usually settle within a few weeks.
They do climb with dose. In TRIUMPH-1, nausea affected 28.6% of people on 4 mg, 38.4% on 9 mg and 42.4% on 12 mg, against 14.8% on placebo. Smaller meals and an extra four weeks on a dose are the usual fixes. Three things are new.
Skin tingling (dysesthesia)
This one catches switchers off guard. Some people on retatrutide notice skin that tingles, burns or feels unusually sensitive to touch. In TRIUMPH-1 it affected 5.1% on 4 mg, 12.3% on 9 mg and 12.5% on 12 mg, against 0.9% on placebo, and TRIUMPH-4 reported it in 20.9% of people on 12 mg. Most cases were mild.
On tirzepatide, the same sensation was rare: 0.4% at 15 mg in SURMOUNT-1 and -2, according to Lilly. So if your skin starts feeling strange around the 9 mg step, this is the likely reason, and it's worth mentioning to whoever prescribes or supervises your treatment.
A slightly faster heart rate
Expect a few extra beats per minute. In phase 2, resting heart rate rose with dose, by up to about 7 beats per minute, peaked around week 24 and then eased off. A small rise after switching is expected. A racing or irregular heartbeat is not, and needs checking.
Blood sugar, if you have diabetes
Glucose control can shift during the switch. Retatrutide lowered A1C by up to 1.6 percentage points in TRIUMPH-2, which enrolled people with type 2 diabetes. If you take insulin or a sulfonylurea, a stronger drug can push blood sugar too low, so check more often and tell whoever manages your diabetes before you switch.
The full list, with rates for every dose, is in our retatrutide side effects guide.
How to Switch From Tirzepatide to Retatrutide in 6 Steps
Here's the whole switch on one page.
- Take your last tirzepatide dose as scheduled. No need to lower it first.
- Mix and calculate before switch day. Reconstitute the retatrutide vial and work out the units for 2 mg, so you're not doing math with a syringe in your hand.
- Inject 2 mg seven days after the last tirzepatide shot. Keep your usual injection day. Wait 10 to 14 days instead if tirzepatide is still making you sick.
- Hold 2 mg for four weeks. Appetite may feel a little stronger while tirzepatide clears.
- Step up every four weeks, only if you need to. 4, then 6, 9 and 12 mg, staying longer on any dose that brings side effects.
- Log every week. Weight, dose, units, side effects and resting heart rate. It's the only honest way to judge whether the switch is working.
When Switching Isn't the Right Move
Sometimes the better move is staying put. Switching trades a drug with years of approval behind it for one that isn't approved anywhere yet, so it should solve a real problem.
- You're still losing, even slowly. Half a pound a week is still progress, and a switch sends you back to a starting dose.
- You haven't reached 15 mg. The next tirzepatide step is a smaller change than a new drug, and our guide to the tirzepatide plateau covers what to check first.
- You need a prescription drug. Lilly plans to file retatrutide with the FDA in the first quarter of 2027, so insurance coverage and pharmacy supply are unlikely before the second half of 2027.
Cost is the other common reason people look at a switch. If that's you, compare the cheapest tirzepatide options at your current dose first. Direct-from-Lilly vials, savings cards and compounded versions can differ by hundreds of dollars a month, and staying on a drug you already tolerate saves you from starting over at 2 mg.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Retatrutide is still in clinical trials and isn't approved for any use yet, and no study has tested switching to it from tirzepatide. The doses and timing described reflect clinical trial protocols and common practice, not prescriptions. Talk to a licensed healthcare provider before changing any medication, especially if you have diabetes, take insulin or a sulfonylurea, or have a heart condition.